3 news items
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
analysis and reporting, failure to identify and develop additional product candidates, unfavorable pricing regulations, third-party reimbursement
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
product candidates, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
and over, if they are between 6 and 17 years of age when treatment starts. Patients may remain on reimbursed setmelanotide as adults whilst they continue
- Prev
- 1
- Next